Skip to main content
SpringerLink
Log in

Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson’s Disease

  • Chapter
  • First Online:
Leucine-Rich Repeat Kinase 2 (LRRK2)

Part of the book series: Advances in Neurobiology ((NEUROBIOL,volume 14))

Abstract

The discovery of LRRK2 mutations as a cause of Parkinson’s disease (PD), including the sporadic late-onset form, established the decisive role of genetics in the field of PD research. Among LRRK2 mutations, the G2019S, mostly lying in a haplotype originating from a common Middle Eastern ancestor, has been identified in different populations worldwide. The G2385R and R1628P variants represent validated risk factors for PD in Asian populations. Here, we describe in detail the origin, the present worldwide epidemiology, and the penetrance of LRRK2 mutations. Furthermore, this chapter aims to characterize other definitely/probably pathogenic mutations and risk variants of LRRK2. Finally, we provide some general guidelines for a LRRK2 genetic testing and counseling. In summary, LRRK2 discovery revolutionized the understanding of PD etiology and laid the foundation for a promising future of genetics in PD research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276(5321):2045–2047

    Article  CAS  PubMed  Google Scholar 

  2. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J et al (2003) alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302(5646):841

    Article  CAS  PubMed  Google Scholar 

  3. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44(4):595–600

    Article  CAS  PubMed  Google Scholar 

  4. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44(4):601–607

    Article  CAS  PubMed  Google Scholar 

  5. Zimprich A, Benet-Pages A, Struhal W, Graf E, Eck SH, Offman MN et al (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 89(1):168–175

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Vilarino-Guell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ et al (2011) VPS35 mutations in Parkinson disease. Am J Hum Genet 89(1):162–167

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S et al (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676):605–608

    Article  CAS  PubMed  Google Scholar 

  8. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E et al (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299(5604):256–259

    Article  CAS  PubMed  Google Scholar 

  9. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S et al (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304(5674):1158–1160

    Article  CAS  PubMed  Google Scholar 

  10. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP et al (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38(10):1184–1191

    Article  CAS  PubMed  Google Scholar 

  11. Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW et al (2009) Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 65(1):19–23

    Article  PubMed  Google Scholar 

  12. Di Fonzo A, Dekker MC, Montagna P, Baruzzi A, Yonova EH, Correia Guedes L et al (2009) FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 72(3):240–245

    Article  PubMed  CAS  Google Scholar 

  13. Shojaee S, Sina F, Banihosseini SS, Kazemi MH, Kalhor R, Shahidi GA et al (2008) Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am J Hum Genet 82(6):1375–1384

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Edvardson S, Cinnamon Y, Ta-Shma A, Shaag A, Yim YI, Zenvirt S et al (2012) A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One 7(5), e36458

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Quadri M, Fang M, Picillo M, Olgiati S, Breedveld GJ, Graafland J et al (2013) Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum Mutat 34(9):1208–1215

    Article  CAS  PubMed  Google Scholar 

  16. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E et al (1998) The ubiquitin pathway in Parkinson’s disease. Nature 395(6701):451–452

    Article  CAS  PubMed  Google Scholar 

  17. Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D et al (2005) Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum Mol Genet 14(15):2099–2111

    Article  CAS  PubMed  Google Scholar 

  18. Lautier C, Goldwurm S, Durr A, Giovannone B, Tsiaras WG, Pezzoli G et al (2008) Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet 82(4):822–833

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Chartier-Harlin MC, Dachsel JC, Vilarino-Guell C, Lincoln SJ, Lepretre F, Hulihan MM et al (2011) Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 89(3):398–406

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Vilarino-Guell C, Rajput A, Milnerwood AJ, Shah B, Szu-Tu C, Trinh J et al (2014) DNAJC13 mutations in Parkinson disease. Hum Mol Genet 23(7):1794–1801

    Article  PubMed  CAS  Google Scholar 

  21. Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V et al (1998) A susceptibility locus for Parkinson’s disease maps to chromosome 2p13. Nat Genet 18(3):262–265

    Article  CAS  PubMed  Google Scholar 

  22. Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA et al (2002) Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 70(4):985–993

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C et al (2002) Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet 71(1):124–135

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Singleton AB, Farrer MJ, Bonifati V (2013) The genetics of Parkinson’s disease: progress and therapeutic implications. Mov Disord 28(1):14–23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gonzalez-Perez A, Gayan J, Marin J, Galan JJ, Saez ME, Real LM et al (2009) Whole-genome conditional two-locus analysis identifies novel candidate genes for late-onset Parkinson’s disease. Neurogenetics 10(3):173–181

    Article  CAS  PubMed  Google Scholar 

  26. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW et al (2009) Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 124(6):593–605

    Article  CAS  PubMed  Google Scholar 

  27. Sutherland GT, Halliday GM, Silburn PA, Mastaglia FL, Rowe DB, Boyle RS et al (2009) Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson’s disease? Mov Disord 24(6):833–838

    Article  PubMed  Google Scholar 

  28. Skipper L, Wilkes K, Toft M, Baker M, Lincoln S, Hulihan M et al (2004) Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am J Hum Genet 75(4):669–677

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Tobin JE, Latourelle JC, Lew MF, Klein C, Suchowersky O, Shill HA et al (2008) Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD study. Neurology 71(1):28–34

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zabetian CP, Hutter CM, Factor SA, Nutt JG, Higgins DS, Griffith A et al (2007) Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson’s disease. Ann Neurol 62(2):137–144

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Saiki M, Baker A, Williams-Gray CH, Foltynie T, Goodman RS, Taylor CJ et al (2010) Association of the human leucocyte antigen region with susceptibility to Parkinson’s disease. J Neurol Neurosurg Psychiatry 81(8):890–891

    Article  PubMed  Google Scholar 

  32. Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D et al (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat Genet 42(9):781–785

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R (2004) Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 351(19):1972–1977

    Article  CAS  PubMed  Google Scholar 

  34. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F (2002) A new locus for Parkinson’s disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 51(3):296–301

    Article  CAS  PubMed  Google Scholar 

  35. Hasegawa K, Stoessl AJ, Yokoyama T, Kowa H, Wszolek ZK, Yagishita S (2009) Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 15(4):300–306

    Article  PubMed  Google Scholar 

  36. Zimprich A, Muller-Myhsok B, Farrer M, Leitner P, Sharma M, Hulihan M et al (2004) The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 74(1):11–19

    Article  CAS  PubMed  Google Scholar 

  37. Paisan-Ruiz C, Saenz A, Lopez de Munain A, Marti I, Martinez Gil A, Marti-Masso JF et al (2005) Familial Parkinson’s disease: clinical and genetic analysis of four Basque families. Ann Neurol 57(3):365–372

    Article  PubMed  Google Scholar 

  38. Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ et al (2004) Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62(9):1619–1622

    Article  CAS  PubMed  Google Scholar 

  39. Di Fonzo A, Rohe CF, Ferreira J, Chien HF, Vacca L, Stocchi F et al (2005) A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. Lancet 365(9457):412–415

    Article  PubMed  CAS  Google Scholar 

  40. Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ et al (2005) A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet 365(9457):415–416

    CAS  PubMed  Google Scholar 

  41. Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA et al (2005) Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease. Lancet 365(9457):410–412

    CAS  PubMed  Google Scholar 

  42. Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J et al (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76(4):672–680

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H et al (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57(6):918–921

    Article  CAS  PubMed  Google Scholar 

  44. Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S et al (2006) LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med 354(4):422–423

    Article  CAS  PubMed  Google Scholar 

  45. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M et al (2006) LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N Engl J Med 354(4):424–425

    Article  CAS  PubMed  Google Scholar 

  46. Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C et al (2007) Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson’s disease families. Mov Disord 22(1):55–61

    Article  PubMed  Google Scholar 

  47. Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M et al (2005) G2019S LRRK2 mutation in French and North African families with Parkinson’s disease. Ann Neurol 58(5):784–787

    Article  CAS  PubMed  Google Scholar 

  48. Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S et al (2006) Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson’s disease patients from 18 countries. Mov Disord 21(8):1102–1108

    Article  PubMed  Google Scholar 

  49. Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J et al (2006) Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 67(10):1786–1791

    Article  CAS  PubMed  Google Scholar 

  50. Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M et al (2006) Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci 251(1–2):102–106

    Article  CAS  PubMed  Google Scholar 

  51. Djaldetti R, Hassin-Baer S, Farrer MJ, Vilarino-Guell C, Ross OA, Kolianov V et al (2008) Clinical characteristics of Parkinson’s disease among Jewish Ethnic groups in Israel. J Neural Transm 115(9):1279–1284

    Article  CAS  PubMed  Google Scholar 

  52. Change N, Mercier G, Lucotte G (2008) Genetic screening of the G2019S mutation of the LRRK2 gene in Southwest European, North African, and Sephardic Jewish subjects. Genet Test 12(3):333–339

    Article  CAS  PubMed  Google Scholar 

  53. Saunders-Pullman R, Lipton RB, Senthil G, Katz M, Costan-Toth C, Derby C et al (2006) Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia. Neurosci Lett 402(1–2):92–96

    Article  CAS  PubMed  Google Scholar 

  54. Bardien S, Marsberg A, Keyser R, Lombard D, Lesage S, Brice A et al (2010) LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson’s disease patients. J Neural Transm 117(7):847–853

    Article  PubMed  Google Scholar 

  55. Yonova-Doing E, Atadzhanov M, Quadri M, Kelly P, Shawa N, Musonda ST et al (2012) Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson’s disease. Parkinsonism Relat Disord 18(5):567–571

    Article  PubMed  Google Scholar 

  56. Cilia R, Sironi F, Akpalu A, Cham M, Sarfo FS, Brambilla T et al (2012) Screening LRRK2 gene mutations in patients with Parkinson’s disease in Ghana. J Neurol 259(3):569–570

    Article  PubMed  Google Scholar 

  57. Okubadejo N, Britton A, Crews C, Akinyemi R, Hardy J, Singleton A et al (2008) Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3. PLoS One 3(10), e3421

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Hanagasi HA, Lohmann E, Dursun B, Honore A, Lesage S, Dogu O et al (2011) LRRK2 mutations are uncommon in Turkey. Eur J Neurol 18(10), e137

    Article  CAS  PubMed  Google Scholar 

  59. Shojaee S, Sina F, Farboodi N, Fazlali Z, Ghazavi F, Ghorashi SA et al (2009) A clinic-based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in Iranian Parkinson’s disease patients. Mov Disord 24(7):1023–1027

    Article  PubMed  Google Scholar 

  60. Bras JM, Guerreiro RJ, Ribeiro MH, Januario C, Morgadinho A, Oliveira CR et al (2005) G2019S dardarin substitution is a common cause of Parkinson’s disease in a Portuguese cohort. Mov Disord 20(12):1653–1655

    Article  PubMed  Google Scholar 

  61. Ferreira JJ, Guedes LC, Rosa MM, Coelho M, van Doeselaar M, Schweiger D et al (2007) High prevalence of LRRK2 mutations in familial and sporadic Parkinson’s disease in Portugal. Mov Disord 22(8):1194–1201

    Article  PubMed  Google Scholar 

  62. Gaig C, Ezquerra M, Marti MJ, Munoz E, Valldeoriola F, Tolosa E (2006) LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 63(3):377–382

    Article  PubMed  Google Scholar 

  63. Gonzalez-Fernandez MC, Lezcano E, Ross OA, Gomez-Esteban JC, Gomez-Busto F, Velasco F et al (2007) Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism Relat Disord 13(8):509–515

    Article  PubMed  Google Scholar 

  64. Infante J, Rodriguez E, Combarros O, Mateo I, Fontalba A, Pascual J et al (2006) LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson’s disease. Neurosci Lett 395(3):224–226

    Article  CAS  PubMed  Google Scholar 

  65. Mata IF, Ross OA, Kachergus J, Huerta C, Ribacoba R, Moris G et al (2006) LRRK2 mutations are a common cause of Parkinson’s disease in Spain. Eur J Neurol 13(4):391–394

    Article  CAS  PubMed  Google Scholar 

  66. Gorostidi A, Ruiz-Martinez J, Lopez de Munain A, Alzualde A, Marti Masso JF (2009) LRRK2 G2019S and R1441G mutations associated with Parkinson’s disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 10(2):157–159

    Article  CAS  PubMed  Google Scholar 

  67. Civitelli D, Tarantino P, Nicoletti G, Ciro Candiano IC, Annesi F, De Marco EV et al (2007) LRRK2 G6055A mutation in Italian patients with familial or sporadic Parkinson’s disease. Clin Genet 71(4):367–370

    Article  CAS  PubMed  Google Scholar 

  68. De Rosa A, Criscuolo C, Mancini P, De Martino M, Giordano IA, Pappata S et al (2009) Genetic screening for LRRK2 gene G2019S mutation in Parkinson’s disease patients from Southern Italy. Parkinsonism Relat Disord 15(3):242–244

    Article  PubMed  Google Scholar 

  69. Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohe CF et al (2006) Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson’s disease. Eur J Hum Genet 14(3):322–331

    Article  PubMed  CAS  Google Scholar 

  70. Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M et al (2005) The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson’s disease and originates from a common ancestor. J Med Genet 42(11), e65

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Marongiu R, Ghezzi D, Ialongo T, Soleti F, Elia A, Cavone S et al (2006) Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with Parkinson’s disease. Mov Disord 21(8):1232–1235

    Article  PubMed  Google Scholar 

  72. Lesage S, Condroyer C, Lannuzel A, Lohmann E, Troiano A, Tison F et al (2009) Molecular analyses of the LRRK2 gene in European and North-African autosomal dominant Parkinson’s disease. J Med Genet 46(7):458–464

    Article  CAS  PubMed  Google Scholar 

  73. Lesage S, Janin S, Lohmann E, Leutenegger AL, Leclere L, Viallet F et al (2007) LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch Neurol 64(3):425–430

    Article  PubMed  Google Scholar 

  74. Lesage S, Leclere L, Lohmann E, Borg M, Ruberg M, Durr A et al (2007) Frequency of the LRRK2 G2019S mutation in siblings with Parkinson’s disease. Neurodegener Dis 4(2–3):195–198

    Article  CAS  PubMed  Google Scholar 

  75. Funalot B, Nichols WC, Perez-Tur J, Mercier G, Lucotte G (2006) Genetic screening for two LRRK2 mutations in French patients with idiopathic Parkinson’s disease. Genet Test 10(4):290–293

    Article  CAS  PubMed  Google Scholar 

  76. Cossu G, van Doeselaar M, Deriu M, Melis M, Molari A, Di Fonzo A et al (2007) LRRK2 mutations and Parkinson’s disease in Sardinia: a Mediterranean genetic isolate. Parkinsonism Relat Disord 13(1):17–21

    Article  PubMed  Google Scholar 

  77. Floris G, Cannas A, Solla P, Murru MR, Tranquilli S, Corongiu D et al (2009) Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson’s disease patients. Parkinsonism Relat Disord 15(4):277–280

    Article  PubMed  Google Scholar 

  78. Kalinderi K, Fidani L, Bostantjopoulou S, Katsarou Z, Kotsis A (2007) The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson’s disease. Eur J Neurol 14(10):1088–1090

    Article  CAS  PubMed  Google Scholar 

  79. Papapetropoulos S, Adi N, Shehadeh L, Bishopric N, Singer C, Argyriou AA et al (2008) Is the G2019S LRRK2 mutation common in all southern European populations? J Clin Neurosci 15(9):1027–1030

    Article  CAS  PubMed  Google Scholar 

  80. Papapetropoulos S, Argyriou AA, Mitsi G, Chroni E (2007) Re: the G2019S LRRK2 mutation is uncommon amongst Greek patients with familial Parkinson’s disease. Eur J Neurol 14(11), e6

    Article  CAS  PubMed  Google Scholar 

  81. Spanaki C, Latsoudis H, Plaitakis A (2006) LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 67(8):1518–1519

    Article  PubMed  Google Scholar 

  82. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL et al (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson’s disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128(Pt 12):2786–2796

    Article  PubMed  Google Scholar 

  83. Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A et al (2006) Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson’s disease cohort. J Neurol Neurosurg Psychiatry 77(5):665–667

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T et al (2005) Lrrk2 pathogenic substitutions in Parkinson’s disease. Neurogenetics 6(4):171–177

    Article  CAS  PubMed  Google Scholar 

  85. Toft M, Haugarvoll K, Ross OA, Farrer MJ, Aasly JO (2007) LRRK2 and Parkinson’s disease in Norway. Acta Neurol Scand Suppl 187:72–75

    Article  CAS  PubMed  Google Scholar 

  86. Carmine Belin A, Westerlund M, Sydow O, Lundstromer K, Hakansson A, Nissbrandt H et al (2006) Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Mov Disord 21(10):1731–1734

    Article  PubMed  Google Scholar 

  87. Hedrich K, Winkler S, Hagenah J, Kabakci K, Kasten M, Schwinger E et al (2006) Recurrent LRRK2 (Park8) mutations in early-onset Parkinson’s disease. Mov Disord 21(9):1506–1510

    Article  PubMed  Google Scholar 

  88. Moller JC, Rissling I, Mylius V, Hoft C, Eggert KM, Oertel WH (2008) The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson’s disease. Eur J Neurol 15(7):743–745

    Article  CAS  PubMed  Google Scholar 

  89. Berg D, Schweitzer K, Leitner P, Zimprich A, Lichtner P, Belcredi P et al (2005) Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson’s disease*. Brain 128(Pt 12):3000–3011

    PubMed  Google Scholar 

  90. Nuytemans K, Rademakers R, Theuns J, Pals P, Engelborghs S, Pickut B et al (2008) Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson’s disease patients. Eur J Hum Genet 16(4):471–479

    Article  CAS  PubMed  Google Scholar 

  91. Macedo MG, Verbaan D, Fang Y, van Rooden SM, Visser M, Anar B et al (2009) Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson’s disease. Mov Disord 24(2):196–203

    Article  PubMed  Google Scholar 

  92. Bech S, Norremolle A, Winge K, Hasholt L, Tommerup N, Svenstrup K et al (2011) The lrrk2 p.Gly2019Ser mutation is uncommon in a Danish cohort with various neurodegenerative disorders. Parkinsonism Relat Disord 17(5):398–399

    Article  PubMed  Google Scholar 

  93. Haubenberger D, Bonelli S, Hotzy C, Leitner P, Lichtner P, Samal D et al (2007) A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson’s disease. Mov Disord 22(11):1640–1643

    Article  PubMed  Google Scholar 

  94. Bialecka M, Hui S, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M (2005) Analysis of LRRK 2 G 2019 S and I 2020 T mutations in Parkinson’s disease. Neurosci Lett 390(1):1–3

    Article  CAS  PubMed  Google Scholar 

  95. Jankovic MZ, Kresojevic ND, Dobricic VS, Markovic VV, Petrovic IN, Novakovic IV et al (2015) Identification of novel variants in LRRK2 gene in patients with Parkinson’s disease in Serbian population. J Neurol Sci 353(1–2):59–62

    Article  CAS  PubMed  Google Scholar 

  96. Bognar C, Baldovic M, Benetin J, Kadasi L, Zatkova A (2013) Analysis of Leucine-rich repeat kinase 2 (LRRK2) and Parkinson protein 2 (parkin, PARK2) genes mutations in Slovak Parkinson disease patients. Gen Physiol Biophys 32(1):55–66

    Article  CAS  PubMed  Google Scholar 

  97. Balicza P, Bereznai B, Takats A, Klivenyi P, Dibo G, Hidasi E et al (2012) The absence of the common LRRK2 G2019S mutation in 120 young onset Hungarian Parkinon’s disease patients. Ideggyogy Sz 65(7–8):239–242

    PubMed  Google Scholar 

  98. Fiala O, Pospisilova L, Prochazkova J, Matejckova M, Martasek P, Novakova L et al (2010) Parkin mutations and phenotypic features in Czech patients with early-onset Parkinson’s disease. Neuro Endocrinol Lett 31(2):187–192

    CAS  PubMed  Google Scholar 

  99. Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV, Zagorovskaya TB, Bagyeva G et al (2007) A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson’s disease in Russia. Eur J Neurol 14(4):413–417

    Article  CAS  PubMed  Google Scholar 

  100. Pchelina SN, Yakimovskii AF, Emelyanov AK, Ivanova ON, Schwarzman AL, Singleton AB (2008) Screening for LRRK2 mutations in patients with Parkinson’s disease in Russia: identification of a novel LRRK2 variant. Eur J Neurol 15(7):692–696

    Article  CAS  PubMed  Google Scholar 

  101. Pchelina SN, Yakimovskii AF, Ivanova ON, Emelianov AK, Zakharchuk AH, Schwarzman AL (2006) G2019S LRRK2 mutation in familial and sporadic Parkinson’s disease in Russia. Mov Disord 21(12):2234–2236

    Article  PubMed  Google Scholar 

  102. Shadrina MI, Illarioshkin SN, Bagyeva G, Bespalova EV, Zagorodskaia TB, Slominskii PA et al (2007) A PARK8 form of Parkinson’s disease: a mutational analysis of the LRRK2 gene in Russian population. Zh Nevrol Psikhiatr Im S S Korsakova 107(3):46–50

    CAS  PubMed  Google Scholar 

  103. Chen-Plotkin AS, Yuan W, Anderson C, McCarty Wood E, Hurtig HI, Clark CM et al (2008) Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 70(7):521–527

    Article  CAS  PubMed  Google Scholar 

  104. Johnson J, Paisan-Ruiz C, Lopez G, Crews C, Britton A, Malkani R et al (2007) Comprehensive screening of a North American Parkinson’s disease cohort for LRRK2 mutation. Neurodegener Dis 4(5):386–391

    Article  CAS  PubMed  Google Scholar 

  105. Kay DM, Zabetian CP, Factor SA, Nutt JG, Samii A, Griffith A et al (2006) Parkinson’s disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord 21(4):519–523

    Article  PubMed  Google Scholar 

  106. Paisan-Ruiz C, Nath P, Washecka N, Gibbs JR, Singleton AB (2008) Comprehensive analysis of LRRK2 in publicly available Parkinson’s disease cases and neurologically normal controls. Hum Mutat 29(4):485–490

    Article  CAS  PubMed  Google Scholar 

  107. Papapetropoulos S, Singer C, Ross OA, Toft M, Johnson JL, Farrer MJ et al (2006) Clinical heterogeneity of the LRRK2 G2019S mutation. Arch Neurol 63(9):1242–1246

    Article  PubMed  Google Scholar 

  108. Patra B, Parsian AJ, Racette BA, Zhao JH, Perlmutter JS, Parsian A (2009) LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson’s disease. Parkinsonism Relat Disord 15(3):175–180

    Article  PubMed  Google Scholar 

  109. Scholz S, Mandel RJ, Fernandez HH, Foote KD, Rodriguez RL, Barton E et al (2006) LRRK2 mutations in a clinic-based cohort of Parkinson’s disease. Eur J Neurol 13(12):1298–1301

    Article  CAS  PubMed  Google Scholar 

  110. Dupre N, Riviere JB, Myers RH, Provencher P, Pourcher E, Emond F et al (2007) LRRK2 is not a significant cause of Parkinson’s disease in French-Canadians. Can J Neurol Sci 34(3):333–335

    Article  PubMed  Google Scholar 

  111. Grimes DA, Racacho L, Han F, Panisset M, Bulman DE (2007) LRRK2 screening in a Canadian Parkinson’s disease cohort. Can J Neurol Sci 34(3):336–338

    Article  CAS  PubMed  Google Scholar 

  112. Mata IF, Cosentino C, Marca V, Torres L, Mazzetti P, Ortega O et al (2009) LRRK2 mutations in patients with Parkinson’s disease from Peru and Uruguay. Parkinsonism Relat Disord 15(5):370–373

    Article  PubMed  Google Scholar 

  113. Perez-Pastene C, Cobb SA, Diaz-Grez F, Hulihan MM, Miranda M, Venegas P et al (2007) Lrrk2 mutations in South America: a study of Chilean Parkinson’s disease. Neurosci Lett 422(3):193–197

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Gatto EM, Parisi V, Converso DP, Poderoso JJ, Carreras MC, Marti-Masso JF et al (2013) The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson’s disease: clinical and demographic characteristics. Neurosci Lett 537:1–5

    Article  CAS  PubMed  Google Scholar 

  115. Camargos ST, Dornas LO, Momeni P, Lees A, Hardy J, Singleton A et al (2009) Familial Parkinsonism and early onset Parkinson’s disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations. Mov Disord 24(5):662–666

    Article  PubMed  PubMed Central  Google Scholar 

  116. Munhoz RP, Wakutani Y, Marras C, Teive HA, Raskin S, Werneck LC et al (2008) The G2019S LRRK2 mutation in Brazilian patients with Parkinson’s disease: phenotype in monozygotic twins. Mov Disord 23(2):290–294

    Article  PubMed  Google Scholar 

  117. Pimentel MM, Moura KC, Abdalla CB, Pereira JS, de Rosso AL, Nicaretta DH et al (2008) A study of LRRK2 mutations and Parkinson’s disease in Brazil. Neurosci Lett 433(1):17–21

    Article  CAS  PubMed  Google Scholar 

  118. Fung HC, Chen CM, Hardy J, Hernandez D, Singleton A, Wu YR (2006) Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson’s disease. Mov Disord 21(6):880–881

    Article  PubMed  Google Scholar 

  119. Lin CH, Tzen KY, Yu CY, Tai CH, Farrer MJ, Wu RM (2008) LRRK2 mutation in familial Parkinson’s disease in a Taiwanese population: clinical, PET, and functional studies. J Biomed Sci 15(5):661–667

    Article  PubMed  Google Scholar 

  120. Lu CS, Simons EJ, Wu-Chou YH, Fonzo AD, Chang HC, Chen RS et al (2005) The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson’s disease. Parkinsonism Relat Disord 11(8):521–522

    Article  PubMed  Google Scholar 

  121. Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E et al (2005) The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson’s disease patients. Neurosci Lett 384(3):327–329

    Article  CAS  PubMed  Google Scholar 

  122. Cho JW, Kim SY, Park SS, Kim HJ, Ahn TB, Kim JM et al (2007) The G2019S LRRK2 mutation is rare in Korean patients with Parkinson’s disease. Can J Neurol Sci 34(1):53–55

    Article  PubMed  Google Scholar 

  123. Choi JM, Woo MS, Ma HI, Kang SY, Sung YH, Yong SW et al (2008) Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 9(4):263–269

    Article  CAS  PubMed  Google Scholar 

  124. Punia S, Behari M, Govindappa ST, Swaminath PV, Jayaram S, Goyal V et al (2006) Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson’s disease patients. Neurosci Lett 409(2):83–88

    Article  CAS  PubMed  Google Scholar 

  125. Zabetian CP, Morino H, Ujike H, Yamamoto M, Oda M, Maruyama H et al (2006) Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease. Neurology 67(4):697–699

    Article  CAS  PubMed  Google Scholar 

  126. Huang Y, Halliday GM, Vandebona H, Mellick GD, Mastaglia F, Stevens J et al (2007) Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson’s disease. Mov Disord 22(7):982–989

    Article  PubMed  Google Scholar 

  127. Mellick GD, Siebert GA, Funayama M, Buchanan DD, Li Y, Imamichi Y et al (2009) Screening PARK genes for mutations in early-onset Parkinson’s disease patients from Queensland, Australia. Parkinsonism Relat Disord 15(2):105–109

    Article  PubMed  Google Scholar 

  128. Hernandez DG, Paisan-Ruiz C, McInerney-Leo A, Jain S, Meyer-Lindenberg A, Evans EW et al (2005) Clinical and positron emission tomography of Parkinson’s disease caused by LRRK2. Ann Neurol 57(3):453–456

    Article  CAS  PubMed  Google Scholar 

  129. Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor SA, Griffith A et al (2006) LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 79(4):752–758

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Watterson GA, Guess HA (1977) Is the most frequent allele the oldest? Theor Popul Biol 11(2):141–160

    Article  CAS  PubMed  Google Scholar 

  131. Warren L, Gibson R, Ishihara L, Elango R, Xue Z, Akkari A et al (2008) A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson’s disease. Parkinsonism Relat Disord 14(1):77–80

    Article  CAS  PubMed  Google Scholar 

  132. Bar-Shira A, Hutter CM, Giladi N, Zabetian CP, Orr-Urtreger A (2009) Ashkenazi Parkinson’s disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries. Neurogenetics 10(4):355–358

    Article  PubMed  Google Scholar 

  133. Lesage S, Patin E, Condroyer C, Leutenegger AL, Lohmann E, Giladi N et al (2010) Parkinson’s disease-related LRRK2 G2019S mutation results from independent mutational events in humans. Hum Mol Genet 19(10):1998–2004

    Article  CAS  PubMed  Google Scholar 

  134. Pirkevi C, Lesage S, Condroyer C, Tomiyama H, Hattori N, Ertan S et al (2009) A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype. Neurogenetics 10(3):271–273

    Article  CAS  PubMed  Google Scholar 

  135. Marder K, Wang Y, Alcalay RN, Mejia-Santana H, Tang MX, Lee A et al (2015) Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology 85(1):89–95

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Healy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, Bressman S et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case–control study. Lancet Neurol 7(7):583–590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Ishihara L, Warren L, Gibson R, Amouri R, Lesage S, Durr A et al (2006) Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol 63(9):1250–1254

    Article  PubMed  Google Scholar 

  138. Brice A (2005) Genetics of Parkinson’s disease: LRRK2 on the rise. Brain 128(Pt 12):2760–2762

    Article  PubMed  Google Scholar 

  139. Marras C, Klein C, Lang AE, Wakutani Y, Moreno D, Sato C et al (2010) LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-phenotype correlation. Neurobiol Aging 31(4):721–722

    Article  CAS  PubMed  Google Scholar 

  140. Dachsel JC, Mata IF, Ross OA, Taylor JP, Lincoln SJ, Hinkle KM et al (2006) Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. Neurosci Lett 410(2):80–84

    Article  PubMed  CAS  Google Scholar 

  141. Paisan-Ruiz C, Lang AE, Kawarai T, Sato C, Salehi-Rad S, Fisman GK et al (2005) LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology 65(5):696–700

    Article  CAS  PubMed  Google Scholar 

  142. Solla P, Cannas A, Floris G, Murru MR, Corongiu D, Tranquilli S et al (2010) Parkin Exon rearrangements and sequence variants in LRRK2 mutations carriers: analysis on a possible modifier effect on LRRK2 penetrance. Parkinsons Dis 2010:537698

    PubMed  PubMed Central  Google Scholar 

  143. Golub Y, Berg D, Calne DB, Pfeiffer RF, Uitti RJ, Stoessl AJ et al (2009) Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. Parkinsonism Relat Disord 15(7):539–541

    Article  PubMed  Google Scholar 

  144. Botta-Orfila T, Ezquerra M, Pastor P, Fernandez-Santiago R, Pont-Sunyer C, Compta Y et al (2012) Age at onset in LRRK2-associated PD is modified by SNCA variants. J Mol Neurosci 48(1):245–247

    Article  CAS  PubMed  Google Scholar 

  145. Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI et al (2008) The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson’s disease: the GenePD study. BMC Med 6:32

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  146. Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D et al (2005) A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65(5):741–744

    Article  CAS  PubMed  Google Scholar 

  147. Tan EK, Skipper L, Chua E, Wong MC, Pavanni R, Bonnard C et al (2006) Analysis of 14 LRRK2 mutations in Parkinson’s plus syndromes and late-onset Parkinson’s disease. Mov Disord 21(7):997–1001

    Article  CAS  PubMed  Google Scholar 

  148. Criscuolo C, De Rosa A, Guacci A, Simons EJ, Breedveld GJ, Peluso S et al (2011) The LRRK2 R1441C mutation is more frequent than G2019S in Parkinson’s disease patients from southern Italy. Mov Disord 26(9):1733–1736

    Article  PubMed  Google Scholar 

  149. Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM et al (2008) Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70(16 Pt 2):1456–1460

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Simon-Sanchez J, Marti-Masso JF, Sanchez-Mut JV, Paisan-Ruiz C, Martinez-Gil A, Ruiz-Martinez J et al (2006) Parkinson’s disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. Mov Disord 21(11):1954–1959

    Article  PubMed  Google Scholar 

  151. Mata IF, Taylor JP, Kachergus J, Hulihan M, Huerta C, Lahoz C et al (2005) LRRK2 R1441G in Spanish patients with Parkinson’s disease. Neurosci Lett 382(3):309–311

    Article  CAS  PubMed  Google Scholar 

  152. Mata IF, Hutter CM, Gonzalez-Fernandez MC, de Pancorbo MM, Lezcano E, Huerta C et al (2009) Lrrk2 R1441G-related Parkinson’s disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics 10(4):347–353

    Article  PubMed  PubMed Central  Google Scholar 

  153. Hatano T, Funayama M, Kubo S, Mata IF, Oji Y, Mori A et al (2014) Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson’s disease. Neurobiol Aging 35(11):2656.e17–2656.e23

    Article  CAS  Google Scholar 

  154. Ross OA, Spanaki C, Griffith A, Lin CH, Kachergus J, Haugarvoll K et al (2009) Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism Relat Disord 15(6):466–467

    Article  PubMed  Google Scholar 

  155. Gaig C, Ezquerra M, Marti MJ, Valldeoriola F, Munoz E, Llado A et al (2008) Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J Neurol Sci 270(1–2):94–98

    Article  CAS  PubMed  Google Scholar 

  156. Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ et al (2006) Biochemical and pathological characterization of Lrrk2. Ann Neurol 59(2):315–322

    Article  CAS  PubMed  Google Scholar 

  157. Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC et al (2006) Lrrk2 and Lewy body disease. Ann Neurol 59(2):388–393

    Article  CAS  PubMed  Google Scholar 

  158. Marti-Masso JF, Ruiz-Martinez J, Bolano MJ, Ruiz I, Gorostidi A, Moreno F et al (2009) Neuropathology of Parkinson’s disease with the R1441G mutation in LRRK2. Mov Disord 24(13):1998–2001

    Article  PubMed  Google Scholar 

  159. Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW et al (2015) Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 72(1):100–105

    Article  PubMed  PubMed Central  Google Scholar 

  160. Biskup S, Mueller JC, Sharma M, Lichtner P, Zimprich A, Berg D et al (2005) Common variants of LRRK2 are not associated with sporadic Parkinson’s disease. Ann Neurol 58(6):905–908

    Article  CAS  PubMed  Google Scholar 

  161. Skipper L, Li Y, Bonnard C, Pavanni R, Yih Y, Chua E et al (2005) Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson’s disease. Hum Mol Genet 14(23):3549–3556

    Article  CAS  PubMed  Google Scholar 

  162. Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, Rohe CF et al (2006) A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan. Neurogenetics 7(3):133–138

    Article  PubMed  CAS  Google Scholar 

  163. Tan EK (2006) Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson’s disease. Ann Acad Med Singapore 35(11):840–842

    PubMed  Google Scholar 

  164. Fung HC, Chen CM, Hardy J, Singleton AB, Wu YR (2006) A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol 6:47

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  165. Farrer MJ, Stone JT, Lin CH, Dachsel JC, Hulihan MM, Haugarvoll K et al (2007) Lrrk2 G2385R is an ancestral risk factor for Parkinson’s disease in Asia. Parkinsonism Relat Disord 13(2):89–92

    Article  PubMed  Google Scholar 

  166. Funayama M, Li Y, Tomiyama H, Yoshino H, Imamichi Y, Yamamoto M et al (2007) Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 18(3):273–275

    Article  CAS  PubMed  Google Scholar 

  167. Tan EK, Zhao Y, Tan L, Lim HQ, Lee J, Yuen Y et al (2007) Analysis of LRRK2 Gly2385Arg genetic variant in non-Chinese Asians. Mov Disord 22(12):1816–1818

    Article  PubMed  Google Scholar 

  168. Li C, Ting Z, Qin X, Ying W, Li B, Guo Qiang L et al (2007) The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson’s disease. Mov Disord 22(16):2439–2443

    Article  PubMed  Google Scholar 

  169. An XK, Peng R, Li T, Burgunder JM, Wu Y, Chen WJ et al (2008) LRRK2 Gly2385Arg variant is a risk factor of Parkinson’s disease among Han-Chinese from mainland China. Eur J Neurol 15(3):301–305

    Article  PubMed  Google Scholar 

  170. Zabetian CP, Yamamoto M, Lopez AN, Ujike H, Mata IF, Izumi Y et al (2009) LRRK2 mutations and risk variants in Japanese patients with Parkinson’s disease. Mov Disord 24(7):1034–1041

    Article  PubMed  PubMed Central  Google Scholar 

  171. Miyake Y, Tsuboi Y, Koyanagi M, Fujimoto T, Shirasawa S, Kiyohara C et al (2010) LRRK2 Gly2385Arg polymorphism, cigarette smoking, and risk of sporadic Parkinson’s disease: a case–control study in Japan. J Neurol Sci 297(1–2):15–18

    Article  CAS  PubMed  Google Scholar 

  172. Kim JM, Lee JY, Kim HJ, Kim JS, Shin ES, Cho JH et al (2010) The LRRK2 G2385R variant is a risk factor for sporadic Parkinson’s disease in the Korean population. Parkinsonism Relat Disord 16(2):85–88

    Article  PubMed  Google Scholar 

  173. Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G et al (2011) Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: a case–control study. Lancet Neurol 10(10):898–908

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. Gopalai AA, Lim SY, Chua JY, Tey S, Lim TT, Mohamed Ibrahim N et al (2014) LRRK2 G2385R and R1628P mutations are associated with an increased risk of Parkinson’s disease in the Malaysian population. Biomed Res Int 2014:867321

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  175. Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter CA et al (2007) LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology 69(18):1737–1744

    Article  CAS  PubMed  Google Scholar 

  176. Xiromerisiou G, Hadjigeorgiou GM, Gourbali V, Johnson J, Papakonstantinou I, Papadimitriou A et al (2007) Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson’s disease: identification of two novel LRRK2 variants. Eur J Neurol 14(1):7–11

    Article  CAS  PubMed  Google Scholar 

  177. Skipper L, Shen H, Chua E, Bonnard C, Kolatkar P, Tan LC et al (2005) Analysis of LRRK2 functional domains in nondominant Parkinson disease. Neurology 65(8):1319–1321

    Article  CAS  PubMed  Google Scholar 

  178. Schlitter AM, Woitalla D, Mueller T, Epplen JT, Dekomien G (2006) The LRRK2 gene in Parkinson’s disease: mutation screening in patients from Germany. J Neurol Neurosurg Psychiatry 77(7):891–892

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  179. Covy JP, Yuan W, Waxman EA, Hurtig HI, Van Deerlin VM, Giasson BI (2009) Clinical and pathological characteristics of patients with leucine-rich repeat kinase-2 mutations. Mov Disord 24(1):32–39

    Article  PubMed  PubMed Central  Google Scholar 

  180. Aasly JO, Vilarino-Guell C, Dachsel JC, Webber PJ, West AB, Haugarvoll K et al (2010) Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson’s disease. Mov Disord 25(13):2156–2163

    Article  PubMed  PubMed Central  Google Scholar 

  181. Lorenzo-Betancor O, Samaranch L, Ezquerra M, Tolosa E, Lorenzo E, Irigoyen J et al (2012) LRRK2 haplotype-sharing analysis in Parkinson’s disease reveals a novel p.S1761R mutation. Mov Disord 27(1):146–151

    Article  CAS  PubMed  Google Scholar 

  182. Cilia R, Siri C, Rusconi D, Allegra R, Ghiglietti A, Sacilotto G et al (2014) LRRK2 mutations in Parkinson’s disease: confirmation of a gender effect in the Italian population. Parkinsonism Relat Disord 20(8):911–914

    Article  PubMed  PubMed Central  Google Scholar 

  183. Clarimon J, Pagonabarraga J, Paisan-Ruiz C, Campolongo A, Pascual-Sedano B, Marti-Masso JF et al (2008) Tremor dominant parkinsonism: clinical description and LRRK2 mutation screening. Mov Disord 23(4):518–523

    Article  PubMed  Google Scholar 

  184. Ross OA, Wu YR, Lee MC, Funayama M, Chen ML, Soto AI et al (2008) Analysis of Lrrk2 R1628P as a risk factor for Parkinson’s disease. Ann Neurol 64(1):88–92

    Article  CAS  PubMed  Google Scholar 

  185. Tan EK, Tan LC, Lim HQ, Li R, Tang M, Yih Y et al (2008) LRRK2 R1628P increases risk of Parkinson’s disease: replication evidence. Hum Genet 124(3):287–288

    Article  CAS  PubMed  Google Scholar 

  186. Lu CS, Wu-Chou YH, van Doeselaar M, Simons EJ, Chang HC, Breedveld GJ et al (2008) The LRRK2 Arg1628Pro variant is a risk factor for Parkinson’s disease in the Chinese population. Neurogenetics 9(4):271–276

    Article  CAS  PubMed  Google Scholar 

  187. Tan EK, Tang M, Tan LC, Wu YR, Wu RM, Ross OA et al (2008) Lrrk2 R1628P in non-Chinese Asian races. Ann Neurol 64(4):472–473

    Article  PubMed  Google Scholar 

  188. Goldwurm S, Zini M, Mariani L, Tesei S, Miceli R, Sironi F et al (2007) Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 68(14):1141–1143

    Article  CAS  PubMed  Google Scholar 

  189. McInerney-Leo A (2005) Genetic testing in Parkinson’s disease. Mov Disord 20(7):908–909

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

The author declares no conflicts of interest.

Author information

Authors and Affiliations

  1. IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

    Edoardo Monfrini & Alessio Di Fonzo

Authors
  1. Edoardo Monfrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessio Di Fonzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessio Di Fonzo .

Editor information

Editors and Affiliations

  1. Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece

    Hardy J. Rideout

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Monfrini, E., Di Fonzo, A. (2017). Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson’s Disease. In: Rideout, H. (eds) Leucine-Rich Repeat Kinase 2 (LRRK2). Advances in Neurobiology, vol 14. Springer, Cham. https://doi.org/10.1007/978-3-319-49969-7_1

Download citation

Publish with us

Policies and ethics

Search

Navigation